接受阿卡拉布替尼治疗的患者出血事件评估。 - Suppr

Evaluation of bleeding events in patients receiving acalabrutinib therapy.

作者信息

Kumar Pooja S, Wiczer Tracy, Rosen Lindsay, Pollauf Arthur J, Zheng Amy, Palettas Marilly, Azali Leylah, Bhat Seema A, Byrd John C, Grever Michael R, Rogers Kerry A, Woyach Jennifer A, Kittai Adam S

机构信息

The Ohio State University, Department of Pharmacy, Columbus, OH, USA.

The Ohio State College of Pharmacy, Columbus, OH, USA.

出版信息

Leukemia. 2023 Jul;37(7):1554-1557. doi: 10.1038/s41375-023-01869-1. Epub 2023 Mar 17.

DOI:10.1038/s41375-023-01869-1

PMID:36932166

Abstract

摘要

相似文献

Evaluation of bleeding events in patients receiving acalabrutinib therapy.接受阿卡拉布替尼治疗的患者出血事件评估。

Leukemia. 2023 Jul;37(7):1554-1557. doi: 10.1038/s41375-023-01869-1. Epub 2023 Mar 17.

Comment on: "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients".评论：“接受阿卡拉布替尼单药治疗的慢性淋巴细胞白血病患者的心血管不良事件：762例患者的汇总分析”

Haematologica. 2022 Jun 1;107(6):1489-1490. doi: 10.3324/haematol.2021.280199.

Response to Comment on: "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients".对关于“接受阿卡拉布替尼单药治疗的慢性淋巴细胞白血病患者的心血管不良事件：762例患者的汇总分析”评论的回复

Haematologica. 2022 Jun 1;107(6):1491-1492. doi: 10.3324/haematol.2021.280310.

Acalabrutinib in chronic lymphocytic leukemia.阿卡拉布替尼治疗慢性淋巴细胞白血病

Expert Opin Pharmacother. 2023 Apr;24(5):545-549. doi: 10.1080/14656566.2023.2194486. Epub 2023 Mar 23.

Acalabrutinib for relapsed chronic lymphocytic leukaemia.阿卡替尼用于复发的慢性淋巴细胞白血病。

Lancet Oncol. 2016 Feb;17(2):e48. doi: 10.1016/S1470-2045(15)00610-5. Epub 2015 Dec 18.

Acalabrutinib: Nursing Considerations for Use in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.阿卡替尼：用于慢性淋巴细胞白血病和小淋巴细胞淋巴瘤患者的护理要点。

Clin J Oncol Nurs. 2021 Dec 1;25(6):687-696. doi: 10.1188/21.CJON.687-696.

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.ASCEND：阿卡替尼对比伊布替尼联合利妥昔单抗或苯达莫司汀联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病的 III 期随机试验。

J Clin Oncol. 2020 Sep 1;38(25):2849-2861. doi: 10.1200/JCO.19.03355. Epub 2020 May 27.

Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.阿卡替尼：一种用于治疗慢性淋巴细胞白血病的布鲁顿酪氨酸激酶抑制剂。

Expert Rev Hematol. 2022 Mar;15(3):183-194. doi: 10.1080/17474086.2022.2054800. Epub 2022 Mar 29.

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.阿卡替尼、维奈托克和奥滨尤妥珠单抗作为慢性淋巴细胞白血病的一线治疗：一项单臂、开放标签、2 期研究。

Lancet Oncol. 2021 Oct;22(10):1391-1402. doi: 10.1016/S1470-2045(21)00455-1. Epub 2021 Sep 14.

Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.阿卡替尼及其在慢性淋巴细胞白血病治疗中的应用。

Future Oncol. 2019 Feb;15(6):579-589. doi: 10.2217/fon-2018-0637. Epub 2018 Nov 1.

引用本文的文献

Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL.一线依鲁替尼治疗的高危慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的真实世界生存结局

Blood Adv. 2025 Aug 12;9(15):3801-3809. doi: 10.1182/bloodadvances.2024015417.

Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: State-of-the-Art Review.布鲁顿酪氨酸激酶抑制剂在慢性淋巴细胞白血病中的心血管毒性：最新综述

JACC CardioOncol. 2023 Oct 17;5(5):570-590. doi: 10.1016/j.jaccao.2023.09.002. eCollection 2023 Oct.

本文引用的文献

Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.评价阿卡替尼单药治疗成熟 B 细胞恶性肿瘤的临床试验安全性数据的汇总分析。

Leukemia. 2021 Nov;35(11):3201-3211. doi: 10.1038/s41375-021-01252-y. Epub 2021 Apr 27.

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.阿卡替尼联合或不联合奥滨尤妥珠单抗对比苯丁酸氮芥联合奥滨尤妥珠单抗治疗初治慢性淋巴细胞白血病（ELEVATE TN）：一项随机、对照、III 期临床试验。

Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2.

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.阿卡替尼单药治疗复发/难治性慢性淋巴细胞白血病患者：更新的 2 期结果。

Blood. 2020 Apr 9;135(15):1204-1213. doi: 10.1182/blood.2018884940.

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.阿卡替尼单药治疗不耐受伊布替尼的慢性淋巴细胞白血病患者。

Blood Adv. 2019 May 14;3(9):1553-1562. doi: 10.1182/bloodadvances.2018030007.

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.伊布替尼和阿卡替尼对血小板功能影响的差异和相似之处。

Haematologica. 2019 Nov;104(11):2292-2299. doi: 10.3324/haematol.2018.207183. Epub 2019 Feb 28.

Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib.接受阿卡拉布替尼治疗的患者不存在接受依鲁替尼治疗的非霍奇金淋巴瘤（NHL）患者中出现的严重血小板功能障碍。

Blood Adv. 2017 Dec 12;1(26):2610-2623. doi: 10.1182/bloodadvances.2017011999.

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.阿卡替尼治疗复发或难治性套细胞淋巴瘤（ACE-LY-004）：一项单臂、多中心、2 期临床试验。

Lancet. 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11.

Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.依鲁替尼相关出血：发病机制、管理及风险降低策略

J Thromb Haemost. 2017 May;15(5):835-847. doi: 10.1111/jth.13651. Epub 2017 Mar 27.

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.阿卡替尼（ACP-196）用于复发的慢性淋巴细胞白血病

N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981. Epub 2015 Dec 7.

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients.在外科患者抗血栓药物临床研究中主要出血的定义。

J Thromb Haemost. 2010 Jan;8(1):202-4. doi: 10.1111/j.1538-7836.2009.03678.x. Epub 2009 Oct 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Evaluation of bleeding events in patients receiving acalabrutinib therapy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献